Home » RX You are browsing entries tagged with “RX”

IMS Health is being stolen

IMS Health is being stolen

It was announced Thursday that IMS Health was to be stolen from its shareholders for $4 billion or about $22 share; a private equity firm will buy them out. IMS Health should have free cash flows this year over $340 million (the actual number should be higher than $400 million, but is benefited by a [...]

November 5 2009 | Posted in Latest, Slider, Stock Analysis! | Read More »

IMS Health – Think Longer-term

IMS Health – Think Longer-term

IMS Health (RX) did not have a spectacular quarter to put it mildly. Revenue decline (on constant currency basis) accelerated to 4% from a 2% decline last quarter. Pharmaceutical companies are becoming more stingy and thus RX’s business got pinched. However, most of the revenue damage is taking place on the consulting side of the [...]

July 25 2009 | Posted in Stock Analysis! | Read More »

Four Reasons Why Investors Are Wrong on IMS Health

Four Reasons Why Investors Are Wrong on IMS Health

The word contrarian is often overused in investing, I have yet to meet an investor who bragged about being a crowd follower; therefore, everyone is a contrarian.  Contrarian investing is very difficult as it requires one to be on the lonely side of the ledger as truly great opportunities present themselves in stocks that everyone [...]

July 16 2009 | Posted in Stock Analysis | Read More »

Pfizer: Blockbuster success is a double-edged sword

Pfizer: Blockbuster success is a double-edged sword

I wrote this article for FT in 2005, but after reading news on Pfizer it feels like I could have written it today.  
Here are some excerpts from the article:

Blockbuster success is a double-edged sword. In this litigious society a discovery of side-effects brings an army of tort lawyers to the doorsteps of pharmaceutical companies. 

The demographic trends [...]

December 4 2006 | Posted in Stock Analysis | Read More »